Calcipotriene
DOVONEX
Pronunciation: kal-si-poe-TRYE-een
“Dove-Cow, poor but trying”
topical psoriasis medication
What it isVitamin D-receptor agonist normalizing keratinocyte proliferation; plaque psoriasis.
Why this oneIt is steroid-sparing and suitable for longer use where topical corticosteroids would cause atrophy.
What limits itIrritation is worst on the face and flexures; treating large areas can cause hypercalcemia.
FDA-approved for
- plaque psoriasis (1993)
FDA label
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Plaque psoriasis (topical) | Adults | Apply thin layer QD–BID | Apply thin layer QD–BID |
Renal Undefined
Hepatic Undefined
Instructions
- Apply a thin layer and rub in gently and completely
- Do not use on the face
Available strengths
- sol 0.005 %
- cream 0.005 %
- ointment 0.005 %
- foam 0.005 %
Contraindications
- Demonstrated hypercalcemia or evidence of vitamin D toxicity
- Do not use on the face
Cautions
- Local skin irritation (burning, itching)
- Hypercalcemia with excessive use
- Facial/scalp psoriasis worsening reported — avoid facial application
Adverse reactions
- Burning
- Itching
- Skin irritation
- Erythema
- Dry skin, peeling, rash, dermatitis
- Worsening of psoriasis
Pregnancy Pregnancy Category C; use only if potential benefit justifies potential fetal risk
Lactation Undefined
Cost
| Strength | #/mo | generic $/unit | CostPlus | |
|---|---|---|---|---|
| 0.005 % | sol | per unit | not offered | |
| 0.005 % | cream | per unit | not offered | |
| 0.005 % | ointment | per unit | not offered |
Generic entry2008
NO BOXED WARNINGS
Principal riskIrritation; hypercalcemia over large areas
Classes and tags
Clinical profile
Legacy pregnancy categoryUnknown / historical label unavailable
Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.